Related Experiment Video
Updated: Jun 3, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion
Mohamed E Abdelrahim1, Khaled H Assi, Henry Chrystyn
1Faculty of Pharmacy, University of Beni Suef, Beni Suef, Egypt.
Aims:
The aim of the study was to determine the relative lung and systemic bioavailability of terbutaline.
Methods:
On separate days healthy volunteers received 500 µg terbutaline study doses either inhaled from a metered dose inhaler or swallowed as a solution with and without oral charcoal. Urine samples were provided at timed intervals post dosing.
Results:
Mean (SD) urinary terbutaline 0.5 h post inhalation, in 12 volunteers, with (IC) and without (I) oral charcoal and oral (O) dosing was 7.4 (2.2), 6.5 (2.1) and 0.2 (0.2) µg. I and IC were similar and both significantly greater than O (P<0.001). Urinary 24 h terbutaline post I was similar to IC + O. The method was linear and reproducible, similar to that of the urinary salbutamol method.
Conclusions:
The urinary salbutamol pharmacokinetic method post inhalation applies to terbutaline. Terbutaline study doses can replace routine salbutamol during these studies when patients are studied.
Related Concept Videos
Measurement of Bioavailability: Pharmacokinetic Methods
Bioavailability: Overview
Bioavailability: Overview
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Drug Excretion: Pulmonary and Glandular Routes
Drugs can also be excreted in breast milk, which is crucial for breastfeeding infants. The process...
One-Compartment Open Model: Urinary Excretion Data and Determination of k
